4F, BUILDING C14, NO. 218, XINGHU STREET, JIANGSU, F4
Reports Unaudited Cash and Cash Equivalents of US$127.9 Million as of June 30, 2026
Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Announces Pricing of US$70.0 Million Public Offering of ADSs
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Reports Full Year 2025 Financial Results and Provides Corporate Update
Provides Business Update and 2026 Objectives
Announces Licensing Agreement for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Material disclosure
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload